Cytokinetics (CYTK) Stock Price, News & Analysis

Company Overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $52.12 to $53.50
• 50-Day Range: $51.22 to $60.16
• 52-Week Range: $25.98 to $110.25
• Volume: 859,208 shs
• Average Volume: 2.25 million shs
• Market Capitalization: $6.19 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $80.67
• Consensus Rating: Moderate Buy

Cytokinetics Stock Analysis - MarketRank™

Cytokinetics scored higher than 89% of companies evaluated by MarketBeat, and ranked 141st out of 996 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 11 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cytokinetics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cytokinetics are expected to grow in the coming year, from ($5.15) to ($4.91) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cytokinetics is -9.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cytokinetics is -9.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.68% of the float of Cytokinetics has been sold short.

Short Interest Ratio / Days to Cover

Cytokinetics has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Cytokinetics has recently decreased by 2.03%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cytokinetics does not currently pay a dividend.

Dividend Growth

Cytokinetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.83

Percentage of Shares Shorted

15.68% of the float of Cytokinetics has been sold short.

Short Interest Ratio / Days to Cover

Cytokinetics has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Cytokinetics has recently decreased by 2.03%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.02

News Sentiment

Cytokinetics has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Cytokinetics this week, compared to 9 articles on an average week.

Search Interest

6 people have searched for CYTK on MarketBeat in the last 30 days.

MarketBeat Follows

Only 2 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,626,227.00 in company stock.

Percentage Held by Insiders

Only 3.40% of the stock of Cytokinetics is held by insiders.

CYTK Stock Analysis - Frequently Asked Questions

How have CYTK shares performed this year?

Cytokinetics' stock was trading at $83.49 at the beginning of 2024. Since then, CYTK stock has decreased by 37.0% and is now trading at $52.63.
View the best growth stocks for 2024 here.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) released its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.06) by $0.25. Cytokinetics's quarterly revenue was down 71.3% compared to the same quarter last year.

When did Cytokinetics' stock split?

Shares of Cytokinetics split before market open on Saturday, January 1st 2000. The 6-1 split was announced on Saturday, January 1st 2000. The newly minted shares were issued to shareholders after the market closes on Tuesday, June 25th 2013. An investor that had 100 shares of stock prior to the split would have 600 shares after the split.

Who are Cytokinetics' major shareholders?

Top institutional shareholders of Cytokinetics include Darwin Global Management Ltd. (4.36%), Marshall Wace LLP (1.60%), Integral Health Asset Management LLC (0.95%) and Pentwater Capital Management LP. Insiders that own company stock include Robert I Blum, Fady Ibraham Malik, Ching Jaw, John T Henderson, B Lynne Parshall, Wendall Wierenga, Muna Bhanji, Robert Wong, Robert Arthur Harrington, Santo J Costa, Edward M Md Kaye, Mark A Schlossberg, L Patrick Gage, David Cragg and Sandford D Smith.
View institutional ownership trends.

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 9/26/2024
• Next Earnings (Estimated): 11/07/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYTK
• CUSIP: N/A
• CIK: 1061983
• Web: www.cytokinetics.com
• Phone: (650) 624-3000
• Fax: 650-624-3010
• Employees: 250
• Year Founded: 1997

Price Target and Rating

• Average Stock Price Target: $80.67
• High Stock Price Target: $106.00
• Low Stock Price Target: $60.00
• Potential Upside/Downside: +52.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 15 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($5.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-526,240,000.00
• Net Margins: -17,398.82%
• Pretax Margin: -17,398.82%
• Return on Equity: N/A
• Return on Assets: -55.97%

Debt

• Debt-to-Equity Ratio: 5.93
• Current Ratio: 10.39
• Quick Ratio: 10.39

Sales & Book Value

• Annual Sales: $7.53 million
• Price / Sales: 828.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.94) per share
• Price / Book: -13.46

Miscellaneous

• Outstanding Shares: 117,660,000
• Free Float: 101,289,000
• Market Cap: $6.24 billion
• Optionable: Optionable
• Beta: 0.77